Eli Lilly and Novo Nordisk are capitalizing on the burgeoning global demand for weight-loss drugs, with Eli Lilly's injectable Mounjaro generating $4.4 billion in international sales in the last quarter, nearly four times its performance from a year prior. Novo Nordisk also reported a 44% increase in international sales of its Wegovy pill, reflecting substantial growth in markets where the drug has yet to launch. Despite the U.S. being a major market for weight-loss drugs, with high obesity rates and a willingness to use pharmaceutical solutions, the international market remains largely untapped, with both companies treating less than 2% of the over one billion individuals affected by obesity globally. Lilly's focus on international expansion is paying off, as 75% of its international weight-loss revenue comes from cash-paying patients. This trend is further supported by the overall 77% growth in the global GLP-1 market over the past year. While prices abroad are generally lower than in the U.S., the increasing demand for weight-loss solutions worldwide indicates a promising future for both companies.